Menu
Search
|

Menu

Close
X

Novus Therapeutics Inc NVUS.OQ (NASDAQ Stock Exchange Capital Market)

6.73 USD
-- (--)
As of Jul 13
chart
Previous Close 6.73
Open --
Volume --
3m Avg Volume 10,209
Today’s High --
Today’s Low --
52 Week High 8.61
52 Week Low 3.13
Shares Outstanding (mil) 9.41
Market Capitalization (mil) 63.31
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.362
FY17
-2.753
FY16
-15.094
FY15
-18.049
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.20
Price to Sales (TTM)
vs sector
--
8.07
Price to Book (MRQ)
vs sector
2.61
4.28
Price to Cash Flow (TTM)
vs sector
--
22.38
Total Debt to Equity (MRQ)
vs sector
0.00
17.39
LT Debt to Equity (MRQ)
vs sector
0.00
13.21
Return on Investment (TTM)
vs sector
-60.99
13.23
Return on Equity (TTM)
vs sector
-61.05
15.28

EXECUTIVE LEADERSHIP

Keith Katkin
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Catherine Turkel
President, Since 2017
Salary: --
Bonus: --
Gregory Flesher
Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Jon Kuwahara
Senior Vice President - Finance and Administration, Since 2017
Salary: --
Bonus: --
Erez Chimovits
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

19900 Macarthur Blvd Ste 550
IRVINE   CA   92612-8426

Phone: +1949.2388090

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.

SPONSORED STORIES